%20V2.jpg)
The Bellcast
Bridge the investing and markets knowledge gap with the Bell Direct Bellcast. From bite-size thought snippets, to full length interviews with the top executives of leading ASX200 companies, you'll be informed and ready for any market movement.
The Bellcast
From the helm: Immutep's (ASX:IMM) Executive Director & CEO Marc Voigt
•
Bell Direct
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep's (ASX:IMM) Executive Director and CEO, Marc Voigt.
Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.
In this video Marc discusses:
- (0:40) What IMM does and its key strength in the market
- (1:27) The impact of the FDA's recent feedback on its lead product
- (2:53) IMM's collaborations with big pharma names like Pfizer & Merck
- (4:03) When to expect data from its current clinical trials
- (5:10) What's coming up for IMM
Note: This interview was filmed on 22 March 2022.